

Karin Hoogendoorn, PharmD

Chair, Cell and Gene Therapies Committee



Karin Hoogendoorn has over 20 years of experience in the pharmaceutical industry, predominantly in the field of advanced therapy medicinal products (ATMPs), monoclonal antibodies and (viral vector based) vaccines. Karin has had various roles of increasing responsibility covering chemical, manufacturing and controls (CMC) and regulatory affairs from pre-clinical to commercial phases, always with a global focus. She worked for small, medium and large pharmacy companies in the Netherlands, Switzerland, Sweden and Japan. She also spent some time in academia in the area of translational research for ATMPs. Currently, she holds a position as head pre-clinical services cell & gene therapy products at the global operating contract development and manufacturing organization Lonza. Karin is actively involved in commenting on European and other regional/national guidelines and standards. She holds MSc degrees in Biology and Bio-Pharmaceutical Sciences from Leiden University and a PharmD degree from Utrecht University, The Netherlands.